Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.
Adults
RSV
Respiratory syncytial virus
Sequelae
Systematic review
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
24
01
2024
accepted:
05
04
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
24
5
2024
Statut:
aheadofprint
Résumé
Respiratory syncytial virus (RSV) can cause severe respiratory infections in adults; however, information on associated sequelae is limited. This systematic literature review aimed to identify sequelae in adults within 1 year following RSV-related hospitalization or resolution of acute infection. Studies were identified from Embase, MEDLINE, LILACS, SciELO, and grey literature. Random-effects meta-analyses using restricted maximum likelihood were used to calculate the proportions and relative risks of sequelae in patients with RSV compared with controls (patients with RSV-negative influenza-like illness, influenza, and parainfluenza) per follow-up period, population, and treatment setting, where possible. Twenty-one relevant studies covering the period from 1990 to 2019 were included. Among the general population, the most frequent clinical sequela was sustained function loss (33.5% [95% CI 27.6-39.9]). Decline in lung function and cardiovascular event or congestive heart failure were also identified. Utilization sequelae were readmission (highest at > 6 months after discharge) and placement in a skilled nursing facility. The only subpopulation with data regarding sequelae was transplant patients. Among lung transplant patients, the most frequently reported clinical sequelae were decline in lung function, followed by graft dysfunction and bronchiolitis obliterans syndrome. Pooled relative risks were calculated for the following sequela with controls (primarily influenza-positive patients): cardiovascular event (general population) and pulmonary impairment (hematogenic-transplant patients) both 1.4 (95% CI 1.0-2.0) and for readmission (general population) 1.2 (95% CI 1.1-1.3). Although less data are available for RSV than for influenza or other lower respiratory tract infections, RSV infection among adults is associated with medically important sequelae, with a prevalence similar to other respiratory pathogens. RSV sequelae should be included in disease burden estimates.
Identifiants
pubmed: 38789901
doi: 10.1007/s40121-024-00974-7
pii: 10.1007/s40121-024-00974-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Public Health England. Respiratory syncytial virus. In: Respiratory syncytial virus: the green book [Internet]. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/458469/Green_Book_Chapter_27a_v2_0W.PDF . Accessed 16 June 2022.
Atamna A, Babich T, Froimovici D, et al. Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: comparison with seasonal influenza. Int J Infect Dis. 2021;103:489–93.
pubmed: 33249288
doi: 10.1016/j.ijid.2020.11.185
Li Y, Kulkarni D, Begier E, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;12(4):1137–49.
pubmed: 36941483
pmcid: 10027261
doi: 10.1007/s40121-023-00792-3
Kingwell K. RSV vaccines score landmark FDA approvals. Nat Rev Drug Discov. 2023. https://doi.org/10.1038/d41573-023-00085-x .
doi: 10.1038/d41573-023-00085-x
pubmed: 37923842
Sadoff J, De Paepe E, DeVincenzo J, et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J Infect Dis. 2022;226(3):396–406.
pubmed: 33400792
doi: 10.1093/infdis/jiab003
Shan J, Britton PN, King CL, Booy R. The immunogenicity and safety of respiratory syncytial virus vaccines in development: a systematic review. Influ Other Respir Viruses. 2021;15(4):539–51.
doi: 10.1111/irv.12850
Tin Tin Htar M, Yerramalla MS, Moïsi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e48.
pubmed: 32052719
pmcid: 7078512
doi: 10.1017/S0950268820000400
Sellers SA, Hagan RS, Hayden FG, Fischer Ii WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influ Other Respir Viruses. 2017;11(5):372–93.
doi: 10.1111/irv.12470
Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194–202.
pubmed: 35105985
pmcid: 9127978
doi: 10.1038/s41590-021-01104-y
Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
doi: 10.1136/bmj.g7647
Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209–12.
doi: 10.1080/01621459.1927.10502953
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
pubmed: 12111919
doi: 10.1002/sim.1186
RStudio-Team. RStudio: Integrated Development for R Boston: RStudio, PBC; 2020. http://www.rstudio.com/ . Accessed 16 June 2022.
Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197–203.
pubmed: 30452608
doi: 10.1093/cid/ciy991
Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influ Other Respir Viruses. 2022;16(6):1151–60.
doi: 10.1111/irv.13043
Branche A, Granieri E, Walsh E, et al. Incidence and evaluation of the change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Open Forum Infect Dis. 2018;5(suppl_1):S263.
pmcid: 6253700
doi: 10.1093/ofid/ofy210.740
Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958–62.
pubmed: 25753833
doi: 10.1016/j.healun.2015.01.009
Chorazka M, Flury D, Herzog K, Albrich WC, Vuichard-Gysin D. Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection. PLoS ONE. 2021;16(7):e0253161.
pubmed: 34292983
pmcid: 8297903
doi: 10.1371/journal.pone.0253161
Damlaj M, Bartoo G, Cartin-Ceba R, et al. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016;18(2):216–26.
pubmed: 26909896
doi: 10.1111/tid.12513
Han M, Smyth L, Schembri S. Effect of respiratory syncytial virus infection compared to influenza infection on cardiovascular events. Respirology. 2021;26(S2):201.
Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):876–81.
pubmed: 18658110
doi: 10.1164/rccm.200711-1657OC
Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170(2):181–7.
pubmed: 15130908
doi: 10.1164/rccm.200310-1359OC
Ko JP, Shepard J-AO, Sproule MW, et al. CT manifestations of respiratory syncytial virus infection in lung transplant recipients. J Comput Assist Tomogr. 2000;24(2):235.
pubmed: 10752884
doi: 10.1097/00004728-200003000-00009
Lafoeste H, Picard C, Azuar-Beaumont L, et al. Impact of respiratory syncytial virus infection on long-term outcomes in lung transplant recipients. Transpl Int. 2017;30:30.
Mahan LD, Points A, Mohanka MR, et al. Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection. Transpl Infect Dis. 2021;23(4):e13661.
pubmed: 34159688
doi: 10.1111/tid.13661
Permpalung N, Thaniyavarn T, Saullo JH, et al. Impact of respiratory syncytial virus infection on bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2019;38(4):S312–3.
doi: 10.1016/j.healun.2019.01.788
Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589–96.
pubmed: 23298855
pmcid: 3667608
doi: 10.1016/j.bbmt.2012.12.019
Sheshadri A, Chemaly RF, Alousi AM, et al. Pulmonary impairment after respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2019;25(4):800–9.
pubmed: 30521974
doi: 10.1016/j.bbmt.2018.11.022
Testaert H, Bouet M, Valour F, et al. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study. Clin Microbiol Infect. 2021;27(6):897–903.
pubmed: 32827713
doi: 10.1016/j.cmi.2020.07.050
Wyffels V, Kariburyo F, Gavart S, Fleischhackl R, Yuce H. A real-world analysis of patient characteristics and predictors of hospitalization among us medicare beneficiaries with respiratory syncytial virus infection. Adv Ther. 2020;37(3):1203–17.
pubmed: 32026380
pmcid: 7223753
doi: 10.1007/s12325-020-01230-3
Descamps A, Lenzi N, Galtier F, et al. In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017–2019: an observational study. Eur Respir J. 2022;59(3):2100651.
pubmed: 34446468
doi: 10.1183/13993003.00651-2021
Martín-Cerezuela M, Cuéllar-Monreal MJ, Monte-Boquet E, Solé-Jover A, Poveda-Andrés JL. Oral ribavirin for treatment of respiratory syncytial virus in lung transplantation recipients. Transpl Proc. 2021;53(9):2702–5.
doi: 10.1016/j.transproceed.2021.08.037
Uçkay I, Gasche-Soccal PM, Kaiser L, et al. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant. 2010;29(3):299–305.
pubmed: 19837611
doi: 10.1016/j.healun.2009.08.012
Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–21.
pubmed: 26452996
doi: 10.1016/j.healun.2015.08.012
Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695–9.
pubmed: 33180754
pmcid: 7660660
doi: 10.15585/mmwr.mm6945e2
Girard TD, Self WH, Edwards KM, et al. Long-term cognitive impairment after hospitalization for community-acquired pneumonia: a prospective cohort study. J Gen Intern Med. 2018;33(6):929–35.
pubmed: 29374359
pmcid: 5975139
doi: 10.1007/s11606-017-4301-x
Mahan LD, Lill I, Halverson Q, et al. Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation. Transpl Infect Dis. 2021;23(6):e13739.
pubmed: 34605596
pmcid: 8646912
doi: 10.1111/tid.13739
Boe DM, Boule LA, Kovacs EJ. Innate immune responses in the ageing lung. Clin Exp Immunol. 2017;187(1):16–25.
pubmed: 27711979
doi: 10.1111/cei.12881
Dobrzynski DM Jr, Ndi DN, Zhu Y, Markus T, Schaffner W, Talbot HK. Hospital readmissions after laboratory-confirmed influenza hospitalization. J Infect Dis. 2020;222(4):583–9.
pubmed: 32179919
doi: 10.1093/infdis/jiaa117
Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: a systematic review and meta-analysis. J Med Virol. 2022;94(1):44–53.
pubmed: 34411311
doi: 10.1002/jmv.27281
Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5(8):2031–6.
pubmed: 15996256
pmcid: 7187759
doi: 10.1111/j.1600-6143.2005.00971.x
Caldeira D, Rodrigues B, David C, Costa J, Pinto FJ, Ferreira JJ. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Rev Vaccines. 2019;18(11):1211–7.
pubmed: 31693865
doi: 10.1080/14760584.2019.1690459
MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953–6.
pubmed: 27686519
doi: 10.1136/heartjnl-2016-309983
Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2019;24(1):109–14.
pubmed: 30367316
doi: 10.1007/s10741-018-9736-6
Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10(6):e019636.
pubmed: 33719496
pmcid: 8174205
doi: 10.1161/JAHA.120.019636
Pischedda S, Rivero-Calle I, Gómez-Carballa A, et al. Role and diagnostic performance of host epigenome in respiratory morbidity after RSV infection: the EPIRESVi study. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.875691 .
doi: 10.3389/fimmu.2022.875691
pubmed: 35619695
pmcid: 9128527
Kim JY, Han K, Suh YJ. Prevalence of abnormal cardiovascular magnetic resonance findings in recovered patients from COVID-19: a systematic review and meta-analysis. J Cardiovasc Magn Reson. 2021;23(1):100.
pubmed: 34479603
pmcid: 8414035
doi: 10.1186/s12968-021-00792-7
Guardado M, Theilacker C, Sato R, et al. Abstract 294/#310 Sequelae of pneumococcal pneumonia in adults: a systematic literature review. ISPPD. 2022.
Weinberger B. Vaccination of older adults: influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing. 2021;18(1):38.
pubmed: 34627326
pmcid: 8501352
doi: 10.1186/s12979-021-00249-6
Ramirez J, Carrico R, Wilde A, et al. Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR. Infect Dis Ther. 2023;12(6):1593–603.
pubmed: 37148463
pmcid: 10163290
doi: 10.1007/s40121-023-00805-1
Onwuchekwa C, Moreo LM, Menon S, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228(2):173–84.
pubmed: 36661222
pmcid: 10345483
doi: 10.1093/infdis/jiad012
Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12(2):677–85.
pubmed: 36707466
pmcid: 9883084
doi: 10.1007/s40121-023-00758-5
Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548–58.
pubmed: 17176570
pmcid: 3290928
doi: 10.3201/eid1210.051015
Prosser LA, Lavelle TA, Fiore AE, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS ONE. 2011;6(7):e22308.
pubmed: 21829456
pmcid: 3146485
doi: 10.1371/journal.pone.0022308
Chen C, Cervero Liceras F, Flasche S, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2019;7(1):e58–67.
pubmed: 30554762
doi: 10.1016/S2214-109X(18)30422-4
Owusu-Edusei K, Deb A, Johnson KD. Estimates of the health and economic burden of pneumococcal infections attributable to the 15-valent pneumococcal conjugate vaccine serotypes in the USA. Infect Dis Ther. 2022;11(3):987–99.
pubmed: 35084647
pmcid: 9124246
doi: 10.1007/s40121-022-00588-x
Wateska AR, Patricia Nowalk M, Lin CJ, et al. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old. Vaccine. 2022;40(50):7312–20.
pubmed: 36336526
pmcid: 9999373
doi: 10.1016/j.vaccine.2022.10.066
Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of newly recommended pneumococcal vaccination strategies in older underserved minority adults in the USA. Infect Dis Ther. 2022;11(4):1683–93.
pubmed: 35831685
pmcid: 9334503